Martingale Asset Management’s Dyne Therapeutics DYN Stock Holding History

Martingale Asset Management’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$465K	Buy	25,654 +502	+2%	+$8.66K	0.01%	657
2025 Q4	$492K	Sell	25,152 -1,898	-7%	-$35.9K	0.01%	612
2025 Q3	$342K	Buy	+27,050	New	+$309K	0.01%	673
2023 Q2	–	Sell	-10,441	Closed	-$120K	–	820
2023 Q1	$120K	Sell	10,441 -24,825	-70%	-$322K	﹤0.01%	801
2022 Q4	$409K	Buy	+35,266	New	+$408K	0.01%	659
2022 Q1	–	Sell	-31,814	Closed	-$379K	–	825
2021 Q4	$379K	Buy	+31,814	New	+$447K	﹤0.01%	694

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Martingale Asset Management's DYN Position: Q1 2026 in Review

Martingale Asset Management increased its Dyne Therapeutics (DYN) stake by 2% in Q1 2026, buying an estimated $8.66K and bringing the position to 25,654 shares worth $465K. The position accounts for 0.01% of the portfolio, ranked #657.

Martingale Asset Management first reported a position in DYN in Q4 2021 and has held it in 6 quarters since. The position peaked at $492K in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Martingale Asset Management held 25,654 shares of Dyne Therapeutics worth $465K as of Q1 2026.
Martingale Asset Management bought 502 Dyne Therapeutics shares in Q1 2026, an estimated $8.66K.
Dyne Therapeutics made up 0.01% of Martingale Asset Management's portfolio in Q1 2026, its #657 holding.
Martingale Asset Management first reported a position in Dyne Therapeutics in Q4 2021 and has held it in 6 quarters since.
Martingale Asset Management's Dyne Therapeutics position peaked at $492K in Q4 2025.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Martingale Asset Management's 13F filing for Q1 2026, filed 13 May 2026.